0 item(s)
View cart
You have no items in your shopping cart.
02
Feb
T Lymphocytes: Biology and Cancer Immunotherapy
Key pillars of the adaptive immune system and the forefront of oncology.
T lymphocytes (T cells) are a central component of the adaptive immune system, responsible for the recognition and elimination of infected, transformed, or otherwise abnormal cells. Originating from hematopoietic stem cells in the bone marrow and maturing in the thymus, these cells provide systemic immune surveillance essential for host defense and tumor immunity.
Figure 1: Mechanism of T cell activation and cellular interaction.
T Cell Subsets and Functional Specialization
• CD4⁺ Helper T cells
Coordinate immune responses by secreting cytokines that regulate B cells, macrophages, and CTLs.
• CD8⁺ Cytotoxic T lymphocytes (CTLs)
Directly eliminate target cells via perforin- and granzyme-mediated cytotoxicity.
• Regulatory T cells (Tregs)
Maintain immune tolerance and prevent autoimmunity by suppressing excessive immune activation.
T Cell–Based Immunotherapies
Modern oncology leverages T cell function to selectively target malignant cells through several transformative strategies:
I. Immune Checkpoint Inhibition
By blocking inhibitory pathways like PD-1/PD-L1, these inhibitors restore T cell effector function. This has shown significant success in treating melanoma and non-small cell lung cancer.
II. Adoptive T Cell Therapies
• CAR-T Cell Therapy
Genetic modification of T cells to express Chimeric Antigen Receptors (CARs) for MHC-independent tumor recognition. Highly effective in B cell leukemias.
• Tumor-Infiltrating Lymphocyte (TIL)
Ex vivo expansion of naturally occurring tumor-infiltrating cells, offering high specificity for metastatic melanoma.
• TCR-Engineered T Cell (TCR-T)
Enhancing TCR affinity for specific tumor-derived peptides, showing promise in solid tumors like pancreatic cancer.
III. Combination Therapeutic Strategies
To overcome resistance, BioFargo recognizes the importance of multi-pronged approaches:
- Multi-checkpoint blockade: Concurrent inhibition to enhance activation in refractory cancers.
- Microenvironment modulation: Targeting pathways like PAK4-related signaling to improve T cell infiltration and persistence.
Advancing the Future of Precision Oncology.
Biofargo team
